- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04891809
Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM
Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The treatment goals in elderly patients with multiple myeloma (MM) are similar to those in younger patients: rapid and long-lasting symptom control, deep response and durable remissions as well as increased survival are at the forefront, similar to therapy goals in younger patients. Elderly patients frequently present with comorbidities, reduced treatment tolerance and greater frequency of treatment discontinuations. Hence, treatment needs to be adapted to the specific needs of this patient population.
ln the recent decade lenalidomide-based therapies have been established as effective treatment modalities in elderly patients. In elderly patients lenalidomide + dexamethasone (Rd) is one of the most frequently used treatment regimens, which is effective and well tolerated.
MM is a high unmet medical need and as a result, several agents are currently under clinical investigation in MM. Monoclonal antibodies (mAb) are one of the most promising groups of drugs in development in the treatment of MM with several of them demonstrating activity in this disease. lsatuximab is a highly effective monoclonal antibody with an excellent activity and tolerance profile, active as single agent therapy in patients with multiple prior lines of treatment.
Presently several trials with isatuximab-lenalidomide containing treatment regimens are ongoing. The expected benefits of adding isatuximab to Rd over Rd alone in very elderly patients seem to outweigh possible risks by far.
A greater depth of response is anticipated including greater number of MRD (minimal residual disease) negative patients, higher response rates, and longer progression free survival.
Risk conferred with the addition of isatuximab are mainly restricted to a roughly 40% rate of infusion reactions, which usually are seen at the first infusion only. ln addition, there is an increased risk for grade 4 leukopenia, grade 2 and 3 thrombocytopenia, and grade 3 infection and fatigue.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Daniela Wolkersdorfer
- Phone Number: 4412 +43 662640
- Email: d.wolkersdorfer@agmt.at
Study Locations
-
-
-
Graz, Austria, 8036
- Recruiting
- Med.Univ.Graz, Univ.-Klinikum f. Innere Medizin, Klin. Abt. f. Haematologie
-
Contact:
- Siegfried Sormann, OA, MD
- Phone Number: 81814 +43 316 385
- Email: Siegfried.Sormann@klinikum-graz.at
-
Contact:
- Julia Lodron, MSc. BScN.
- Phone Number: 31188 +43 316 385
- Email: julia.lodron@medunigraz.at
-
Principal Investigator:
- Siegfried Sormann, OA, MD
-
Klagenfurt, Austria, 9020
- Not yet recruiting
- Klinik Klagenfurt am Wörthersee Abteilung für Innere Medizin und Hämatologie und internistische Onkologie
-
Contact:
- Joachim Rettl, Senior MD
- Phone Number: 25119 +43 463 538
- Email: joachim.rettl@kabeg.at
-
Contact:
- Melanie Lang, DGKP
- Phone Number: 28670 +43 463 538
- Email: melanie.lang@kabeg.at
-
Principal Investigator:
- Joachim Rettl, Senior MD
-
Kufstein, Austria, 6330
- Recruiting
- Bezirkskrankenhaus Kufstein, Innere Medizin, Interne II u. onkologische Tagesklinik
-
Contact:
- August Zabernigg, Head MD PD
- Phone Number: 3001 +43 5372 6966
- Email: august.zabernigg@bkh-kufstein.at
-
Contact:
- Sabine Kriesche
- Email: sabine.kriesche@bkh-kufstein.at
-
Principal Investigator:
- August Zabernigg, Head MD PD
-
Leoben, Austria, 8700
- Recruiting
- LKH Hochsteiermark - Leoben, Abt. f. Innere Medizin, Haemato-Onkologie
-
Contact:
- Manuela Maderdonner, BSc.,MSc.
- Phone Number: 3402 +43 3842 401
- Email: manuela.maderdonner@kages.at
-
Contact:
- Thamer Sliwa, MD, DL
- Phone Number: 2821 +43 3842 401
- Email: thamer.sliwa@kages.at
-
Principal Investigator:
- Thamer Sliwa, MD, Head Dept.
-
Linz, Austria, 4021
- Recruiting
- JKU Linz, Univ.-Klinik f. Hämatologie und Internistische Onkologie, MC III.
-
Contact:
- Clemens Schmitt, Prof. MD
- Email: clemens.schmitt@kepleruniklinikum.at
-
Contact:
- Isabella Rauscher, MSc
- Phone Number: 6204 +43 5 7680 83
- Email: isabella.rauscher@kepleruniklinikum.at
-
Principal Investigator:
- Clemens Schmitt, Prof. MD
-
Mitterweng, Austria, 3500
- Recruiting
- Univ.Klinikum Krems, Klin. Abt. f. Innere Medizin 2
-
Contact:
- Klaus Podar, MD, PhD
- Phone Number: 22324 +43 2732 9004
- Email: klaus.podar@krems.lknoe.at
-
Contact:
- Elisabeth Zwickl-Traxler, Mag.
- Email: studienzentrale@krems.lknoe.at
-
Principal Investigator:
- Klaus Podar, MD, PhD
-
Rankweil, Austria, 6830
- Not yet recruiting
- LKH Feldkirch, Innere Medizin II, Interne E: Hämatologie und Onkologie
-
Contact:
- Bernd Hartmann, MD
- Phone Number: 2681 +43 5522 303
- Email: bernd.hartmann@lkhf.at
-
Principal Investigator:
- Bernd Hartmann, MD
-
Salzburg, Austria, 5020
- Recruiting
- PMU Salzburg: Universitätsklinik für Innere Medizin III
-
Contact:
- Richard Greil, Head Prof MD
- Phone Number: 25800 +43 57255
- Email: r.greil@salk.at
-
Contact:
- Michaela Schachner
- Email: m.schachner@salk.at
-
Principal Investigator:
- Richard Greil, Head Prof MD
-
St.Pölten, Austria, 3100
- Recruiting
- Univ.-Klinikum St. Pölten, Innere Medizin 1
-
Contact:
- Petra Pichler, MD
- Phone Number: 22181 +43 2742 9004
- Email: petra.pichler@stpoelten.lknoe.at
-
Principal Investigator:
- Petra Pichler, MD
-
Vienna, Austria, 1090
- Recruiting
- AKH Meduni Wien Universitätsklinik für Innere Medizin I: Klinische Abteilung für Hämatologie und Hämostaseologie
-
Contact:
- Maria-Theresa Krauth, Prof.PD MD
- Phone Number: 44100 +43 1 40400
- Email: maria.krauth@meduniwien.ac.at
-
Contact:
- Phone Number: 57551 +43 1 40160
- Email: renate.schoder@meduniwien.ac.at
-
Principal Investigator:
- Maria-Theresa Krauth, Prof.PD MD
-
Vienna, Austria, 1130
- Not yet recruiting
- Klinik Hietzing, 5. Medizinische Abteilung
-
Contact:
- Daniel Lechner-Radner, Senior MD
- Phone Number: 2239 +43 1 80110
- Email: hietzing.forschung@gmail.com
-
Contact:
- Elmir Graf, Mag.Pharm
- Phone Number: +43 699 119 43 524
- Email: hietzing.forschung@gmail.com
-
Principal Investigator:
- Daniel Lechner-Radner, Senior MD
-
Vienna, Austria, 1160
- Recruiting
- Klinik Ottakring, 1.Med.Abt., Zentrum f. Onkologie, Haematologie und Palliativmedizin
-
Contact:
- Martin Schreder, MD
- Phone Number: 2151 +43 1 491 50
- Email: martin.schreder@gesundheitsverbund.at
-
Principal Investigator:
- Martin Schreder, MD
-
Vienna, Austria, 1060
- Recruiting
- Krankenhaus d. Barmh. Schwestern Wien, 1. Med. Abteilung, Onkologie und Hämatologie
-
Contact:
- Eva M. Autzinger, MD
- Phone Number: +43 1 599 88
- Email: evamaria.autzinger@bhs.at
-
Principal Investigator:
- Eva M. Autzinger, MD
-
Wien, Austria, 1140
- Recruiting
- Hanusch Krankenhaus der Österreichischen Gesundheitskasse, 3. Med. Abteilung
-
Contact:
- Michael Fillitz, MD
- Phone Number: 85500 +43191021
- Email: michael.fillitz@oegk.at
-
Contact:
- Barbara Dixer, BSc
- Phone Number: 85435 +43191021
- Email: barbara.dixer@oegk.at
-
Principal Investigator:
- Michael Fillitz, MD
-
Zams, Austria, 6511
- Recruiting
- Krankenhaus Zams, Innere Medizin, Internistische Onkologie-Haematologie
-
Contact:
- Ewald Wöll, Prof. MD
- Phone Number: 7421 +43 5442 600
- Email: ewald.woell@krankenhaus-zams.at
-
Contact:
- Carmen Ruepp
- Phone Number: 5971 +43 664 600 85
- Email: carmen.ruepp@krankenhaus-zams.at
-
Principal Investigator:
- Ewald Wöll, Prof. MD
-
-
Tirol
-
Innsbruck, Tirol, Austria, 6020
- Withdrawn
- Univ.-Klinik für Innere Medizin V Innsbruck, Abteilung für Hämatologie und Onkologie
-
-
-
-
-
Athens, Greece, 10676
- Recruiting
- General Hospital of Athens "Evangelismos", Hematology Clinic
-
Contact:
- Sosana Delimpasi, MD
- Phone Number: +30 6977204193
- Email: sodeli@yahoo.com
-
Contact:
- George Nakis
- Phone Number: +30 6944822722
- Email: giorgosnakis@yahoo.gr
-
Principal Investigator:
- Sosana Delimpasi, MD
-
Athens, Greece, 11528
- Recruiting
- General Hospital of Athens "Alexandra, Plasma Cell Dyscrasias Unit
-
Contact:
- Evangelos Terpos, Prof.MD
- Phone Number: +30 2132162846
- Email: eterpos@hotmail.com
-
Contact:
- Natasha Stavri
- Phone Number: +30 6985640810
- Email: natashastavri23@gmail.com
-
Principal Investigator:
- Evangelos Terpos, Prof.MD
-
Thessaloníki, Greece, 54639
- Recruiting
- Anticancer Hospital of Thessaloniki "Theageneio", Hematology
-
Contact:
- Eirini Katodrytou, MD,Dir.
- Phone Number: +30 6974 872869
- Email: eirinikatodritou@gmail.com
-
Contact:
- Evdoxia Kallia
- Phone Number: +30 6944186629
- Email: kalliaevi@gmail.com
-
Principal Investigator:
- Eirini Katodrytou, MD,Dir.
-
-
-
-
-
Belgrade, Serbia, 11000
- Recruiting
- University Clinical Center of Serbia, Clinic for Hematology
-
Contact:
- Jelena Bila, MD, Prof
- Phone Number: +38 1638292992
- Email: biladr.jelena@gmail.com
-
Contact:
- Goran Tadic
- Phone Number: +381642410370
- Email: goran.tadic81@yahoo.com
-
Principal Investigator:
- Jelena Bila, MD, Prof.
-
Kragujevac, Serbia, 34000
- Not yet recruiting
- University Clinical Center Kragujevac, Clinic for Hematology
-
Contact:
- Predrag Djurdjevic, MD, Prof.
- Phone Number: +381641663402
- Email: pdjurdjevic@sbb.rs
-
Contact:
- Violeta Trajkovic
- Phone Number: +381655342776
- Email: vikidunja1234@gmail.com
-
Principal Investigator:
- Predrag Djurdjevic, MD, Prof.
-
Niš, Serbia, 18000
- Not yet recruiting
- University Clinical Center Nis, Clinic for Hematology
-
Contact:
- Miodrag Vucic, MD, Prof.
- Phone Number: +38 163405600
- Email: buca.vucic@gmail.com
-
Contact:
- Aleksandra Cosic
- Phone Number: +381605290292
- Email: alexdaki92@gmail.com
-
Principal Investigator:
- Miodrag Vucic, MD, Prof.
-
Novi Sad, Serbia, 21000
- Not yet recruiting
- Clinical Center of Vojvodina, Clinic for Hematology
-
Contact:
- Ivana Urosevic, MD, PhD
- Phone Number: +38169747557
- Email: ivana.urosevic@mf.uns.ac.rs
-
Contact:
- Bosa Sikic
- Phone Number: +381668552477
- Email: bosa.sikic@gmail.com
-
Principal Investigator:
- Ivanka Urosevic, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 70 years
- Able to provide written informed consent in accordance with federal, local, and institutional guidelines
Patients must have newly diagnosed, symptomatic multiple myeloma with evidence of measurable disease (assessed within 21 days prior to randomization)
- Serum M protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
- Urine M protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
- In subjects without detectable serum or urine M-protein, serum-free light chain (SFLC) ≥100 mg/L (involved light chain) and an abnormal FLC ratio
- No prior treatment for multiple myeloma
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2
- Patients at cardiac risk (NYHA >ll) or pre-existing coronary heart disease, or any other clinically relevant cardiac complication) should be scheduled for a baseline ECHO and can only be included if the LVEF is >40%
Adequate organ and bone marrow function within the 21 days prior to randomization defined by:
- Bilirubin < 2 times the upper limit of normal (ULN), Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times the ULN
- absolute neutrophil count (ANC) ≥ 750/mm3 (growth factor support for max 3 days allowed to achieve this value)
- Hemoglobin >8.0 g/dL (Use of erythropoietic stimulating factors and red blood cell [RBC] transfusion per institutional guidelines is allowed, however the most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin.)
- Platelet count >50,000/mm3
- Calculated or measured creatinine clearance (CrCl) of ≥30 mL/min; Calculation should be based on the MDRD formula (age, gender, black/non- black, weight, height)
Exclusion Criteria:
- ECOG status >2
- Patients unlikely to tolerate Rd
- Waldenström macroglobulinemia
- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
- Plasma cell leukemia (> 2.0 x 10^9/L circulating plasma cells by standard differential)
- Myelodysplastic syndrome
- Smoldering Myeloma and MGUS
Second malignancy within the past 5 years except:
- Adequately treated basal cell or squamous cell skin cancer
- Carcinoma in situ of the cervix
- Prostate cancer ≤ Gleason score 6 with stable prostate-specific antigen (PSA over 12 months)
- Ductal breast carcinoma in situ with full surgical resection (i.e., negative margins)
- Treated medullary or papillary thyroid cancer
- History of or current amyloidosis
- Glucocorticoid therapy within the 14 days prior to randomization that exceeds an accumulated dose of 160 mg dexamethasone or 1000 mg prednisone
- Extended field radio therapy (more than 3 fields) within the 21 days prior to randomization
- Contraindication to isatuximab, dexamethasone, lenalidomide or any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs
- Active congestive heart failure (New York Heart Association [NYHA] Class III or IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, acute diffuse infiltrative pulmonary disease, pericardial disease, or myocardial infarction within 4 months prior to enrolment
- Active infection within the 14 days prior to randomization requiring systemic antibiotics and/or antiviral therapy
- Uncontrolled hypertension or uncontrolled diabetes despite medication
- Significant neuropathy (Grade 2 with pain or Grade 3 or higher) within the 14 days prior to randomization
- Known cirrhosis
- Known human immunodeficiency virus (HIV) seropositivity or active hepatitis C or hepatitis B infection (subjects with past hepatitis B virus [HBV] infection or resolved HBV infection defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti HBc] antibody test are eligible; subjects positive for hepatitis C virus [HCV] antibody are eligible only if polymerase chain reaction [PCR] is negative for HCV RNA.)
- Participation in another interventional study within the 28 days prior to randomization
- Major surgery (except kyphoplasty) within the 28 days prior to randomization
- Any other clinically significant medical disease or social condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent, be compliant with study procedures, or provide accurate information.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IRd followed by IR
Induction: 8 cycles isatuximab+lenalidomide+dexamethasone; Maintenance: up to 24 cylces isatuximab+lenalidomide
|
Induction: 10mg/kg on day 1,8,15,22 in cycle 1, subsequently on day 1, 15; every 28 days (q28 days) Maintenance: 10mg/kg, day1, q28 days until progression or intolerance but for a maximum of 24 cycles from start of maintenance
Induction: 25mg*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance *) for patients with moderate renal impairment (30≤ GFR (MDRD formula) < 50 mL/min) starting dose is 10 mg Induction: Patients aged <75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly |
Other: Rd followed by R
Induction: 8 cycles lenalidomide+dexamethasone; Maintenance: up to 24 cylces lenalidomide
|
Induction: 25mg*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance *) for patients with moderate renal impairment (30≤ GFR (MDRD formula) < 50 mL/min) starting dose is 10 mg Induction: Patients aged <75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with MRD (minimal residual disease) negativity (defined by NGF [next generation flow] at 10^-5) after end of induction treatment in the two arms.
Time Frame: After 8 months of induction treatment (8 cycles, each cyle is 28 days)
|
To demonstrate the benefit of isatuximab in combination with lenalidomide and low-dose dexamethasone followed by isatuximab and lenalidomide maintenance therapy in changing the proportion of patients with MRD negativity as compared to lenalidomide and low-dose dexamethasone followed by lenalidomide maintenance treatment in patients with newly diagnosed multiple myeloma (NDMM).
|
After 8 months of induction treatment (8 cycles, each cyle is 28 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients with response to study treatment
Time Frame: After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
|
Effect of treatment on Overall Response Rate (ORR) including patients with Partial Response (PR), Very Good Partial Response (VGPR) and Complete Response (CR) as per International Myeloma Working Group (IMWG) criteria in each arm.
|
After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
|
Progression-free Survival
Time Frame: After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
|
Effectiveness of treatments on Progression-free survival (PFS)
|
After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
|
Overall Survival
Time Frame: After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
|
Effectiveness of treatments on Overall Survival (OS)
|
After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
|
Effectiveness of treatments on MRD negativity
Time Frame: After 20 months (8 months of induction treatment and 12 months of maintenance treatemnent)
|
To evaluate the proportion of patients with MRD negativity (defined by NGF [next generation flow] at 10^-5) after 12 months (13 cycles) of maintenance treatment.
|
After 20 months (8 months of induction treatment and 12 months of maintenance treatemnent)
|
Effectiveness of treatments on preventing progressive disease
Time Frame: After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
|
To evaluate the Time to Progression (TTP) in each arm.
|
After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
|
Progression-free Survival in different high-risk cytogenetic populations
Time Frame: After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
|
Effectiveness of treatment on PFS in high risk cytogenetic populations defined as patients carrying a) del(17p), t(4;14), t(14;16) in each arm and b) the same aberrations plus amp1q21.
|
After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
|
Duration of response
Time Frame: After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
|
Length of time between response and progression or death.
|
After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
|
Incidence of treatment-emergent adverse events (Safety and tolerability)
Time Frame: After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
|
Number of participants with treatment-emergent adverse events as assessed by NCI-CTCAE Version 5.0.
|
After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
|
Changes in quality of life (QoL) using general questionnaire European Organization for Research and Treatment of Cancer (EORTC) Quality of life questionnaire (QLQ) Core 30 (C 30) (EORTC-QLQ-C30)
Time Frame: After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
|
Changes in quality of life will be analyzed by using the cancer patient-specific questionnaire EORTC-QLQ-C30.
|
After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
|
Changes of general health status using questionnaire EQ (EuroQol) 5 dimension (5D) 5 level (5L) (EQ-5D-5L)
Time Frame: After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
|
Changes in general health status will be analyzed by using the questionnaires EQ-5D-5L.
QoL.
|
After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
|
Changes in quality of life (QoL) using multiple myeloma specific questionnaire EORTC-QLQ Myeloma (MY) 20 (EORTC-QLQ-MY20)
Time Frame: After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
|
Changes in quality of life will be analyzed by using the multiple myeloma-specific questionnaire EORTC-QLQ-MY20.
|
After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
|
Progression-free survival after second line therapy
Time Frame: After end of study treatment until 12 months of follow up as a minimum (until LPLV)
|
Influence of potential second line therapy on Progression-free Survival
|
After end of study treatment until 12 months of follow up as a minimum (until LPLV)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Heinz Ludwig, Wilhelminen Cancer Research Institute, Clinic Ottakring
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Lenalidomide
Other Study ID Numbers
- AGMT_MM-4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Newly Diagnosed Multiple Myeloma
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer CenterActive, not recruiting
-
Ain Shams UniversityUnknownNewly Diagnosed Pediatric ITPEgypt
-
Wuerzburg University HospitalClinAssess GmbH; Arbeitsgemeinschaft medikamentoese TumortherapieActive, not recruitingNewly Diagnosed Multiple MyelomaGermany, Austria
-
National Cancer Institute (NCI)RecruitingMultiple Myeloma | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Newly Diagnosed Multiple Myeloma (NDMM)United States
-
Jinling Hospital, ChinaRecruitingNewly Diagnosed Multiple MyelomaChina
-
PETHEMA FoundationBristol-Myers Squibb; Sanofi; Adknoma; Start from scratchNot yet recruitingNewly Diagnosed Multiple MyelomaSpain
-
Larysa SanchezJanssen, LPRecruitingNewly Diagnosed Multiple MyelomaUnited States
-
Nantes University HospitalCompleted
-
PETHEMA FoundationActive, not recruitingNewly Diagnosed Multiple MyelomaSpain
-
Celgene CorporationCompletedNewly Diagnosed Multiple MyelomaSpain, Netherlands, Austria, Australia, Italy, Russian Federation, United Kingdom, Israel, Belgium, Greece, Germany, Poland, Turkey, France, Denmark, Czech Republic, Belarus, Georgia, Ireland, Sweden, Switzerland, Ukraine
Clinical Trials on Isatuximab-Irfc 20 MG/ML [Sarclisa]
-
Thomas Martin, MDWithdrawnRefractory Multiple Myeloma | Relapsed Multiple Myeloma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingSmoldering Plasma Cell MyelomaUnited States
-
Instituto Nacional de Cancerologia de MexicoRoche Pharma AGActive, not recruiting
-
Shaheed Zulfiqar Ali Bhutto Medical UniversityCompletedCytokine Release Syndrome | Covid-19 PneumoniaPakistan
-
AmtixBio Co., Ltd.Novotech (Australia) Pty LimitedCompleted
-
Jadran Galenski laboratorij d.d.CompletedPrimary Open Angle Glaucoma of Both EyesRussian Federation
-
OHSU Knight Cancer InstituteSanofi; Oregon Health and Science UniversityActive, not recruitingRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
Hospital Universitario Ramon y CajalTerminated
-
Guolin WangUnknownEtomidate is Mixed With PropofolChina
-
Merck Sharp & Dohme LLCCompletedNonalcoholic Fatty Liver Disease | Nonalcoholic SteatohepatitisUnited States, Argentina, Australia, Canada, France, Israel, Italy, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Spain, Taiwan, Turkey, Ukraine